Cytori Therapeutics, Inc.
Biotech Specialty Pharma  Advamed Member
3020 Callan Road
San Diego, CA 92121 USA
phone: 858-458-0900
fax: 858-458-0994
Symbol CYTX
Exchange NASDAQ
Founded 1996
Employees 137
www.cytoritx.com
Research Sector Biotech Specialty Pharma
Summary Description
Cell-based therapeutics utilizing stem cells derived from adipose tissue.
Management
Christopher J. Calhoun, Chief Executive Officer; Marc H. Hedrick, M.D., President; Mark E. Saad, Chief Financial Officer
Ownership
Financials Mkt Cap :114


* numbers in thousands

Recent Results
n/a
 
Keywords
Aesthetics, plastic surgery, skin care, orthopedics, advamed

Comment | Printable Version | Jun. 08, 2007
If you work for Cytori Therapeutics, Inc. and want to update this profile, click here

Description
Cytori is discovering and developing proprietary, cell-based therapeutics utilizing adult stem cells derived from adipose, also known as fat tissue. The company's pre-clinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery.
Products / Services
The Company's pipeline of investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery.
Technology / Differentiation
To facilitate processing and delivery of adipose stem cells, Cytori is developing its proprietary Celution system to isolate and concentrate a patient's own stem cells in about an hour.
Market / Customers
n/a
Competitors / Substitutes / Alternatives
Competitors include Baxter International Inc.; Genzyme Biosurgery; Osiris Therapeutics, Inc.
Strategy
n/a
Funding
n/a
Status
Cytori is developing therapeutic stem cells for myocardial infarction and other cardiovascular-related diseases internally. For all other indications and applications outside of cardiovascular disease, the Company is pursuing strategic alliances with biotechnology, medical device, and pharmaceutical companies to accelerate and broaden therapeutic development.
Additional Information
Cytori's MacroPore Biosurgery division develops and manufactures innovative bioresorbable surgical implants. MacroPore Biosurgery manufactures the Hydrosorb family of FDA-cleared bioresorbable spine and orthopedic implants, which are distributed worldwide


2008-08-27-2099